Boston Society Gene and Cell Therapy Conference
Remote attendance alternative will also be provided to accommodate those unable to travel!
March 21, 2024Venue Changed to: Museum of Science The d'Arbeloff Suite (3rd floor/RED WING) Address: 1 Science Park, Boston, MA 02114
|
In Partnership with: |
In Partnership with: |
Confirmed Speakers
Keynote Lecture: Mark Milton, PhD Former Global Head Gene Therapies, PK Sciences @ Novartis Institutes for BioMedical Research - Retired Past, Present, and Future of Gene Therapy |
|||
Glen Banks, PhD Cardiac Gene Therapy Lead @ Bristol Myers Squibb Preclinical Considerations for Development of GTx |
Nicholas Buss, PhD Translational Sciences @ Eli Lilly Gene Therapy and Translational Sciences - How are we doing? |
||
Nagendra Chemuturi, PhD Senior Director ADME @ Eli Lilly Role of DMPK in non-viral GT |
Jennifer Ford, PhD Clinical Pharmacology and Pharmacometrics @ The Janssen Pharmaceutical Companies of Johnson & Johnson Development of AAV-Based Retina Gene Therapy through the Eyes of the Clinical Pharmacologist |
||
Jennifer Jones, PhD Head of Companion Diagnostics @ Spark Therapeutics Pre-existing antibody assays for patient enrollment and Cdx - Title TBA |
Jyoti Malhotra, PhD Executive Director @ Sarepta Therapeutics Learnings from Duchenne Muscular Dystrophy: A Biomarker Perspective |
||
Ronit Mazor, PhD Principal Investigator @ OGT, OTP,CBER, US Food and Drug Administration Can the Immunogenicity of AAV Vectors be Mitigated? |
Kenji Miyazawa, PhD Scientist QSP @ Moderna Construction of an Integrated Translational PBPK-QSP Modeling Platform to Investigate Tissue Distribution & Protein Expression Dynamics of LNP-mRNA Based Therapeutics |
||
Yan Ni, PhD Executive Director, Biomarkers & Precision Medicine @ Passage Bio Leveraging Clinical Diagnostic Assays for Rare Disease Drug Development |
Lei Ci, PhD Associate Scientific Director @ Moderna Assessment of ADME and DDI for LNP-mRNA Therapeutics |
||
Everett Perkins, PhD Executive Director - ADME @ Eli Lilly and Company ADME for In Vivo Genetic Editing: Assessing Effectiveness of Delivery for Editing Cargo |
R. Jude Samulski, PhD Alumni Distinguished Professor, Pharmacology, Member, UNC Gene Therapy Center @ UNC School of Medicine Development of Viral Delivery for Precision Medicine |
||
Brian Wile, PhD General Manager, FlowMetric a KCAS Company Troubleshooting in Flow Cytometry Method Development: Ions, Titers, and Bears (Oh My!)
|
Please Join our LinkedIn Group